Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be announcing earnings results this Tuesday before market ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

Labcorp Holdings Inc. LH, or Labcorp, is slated to report its fourth-quarter 2025 results on Feb. 17, before the market opens. The renowned laboratory service provider reported adjusted earnings of $4 ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...

The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

After hanging out the for sale sign and filing for bankruptcy earlier this year, the genetic testing provider Invitae has found a new home for its portfolio at Labcorp. The two companies announced ...

Competitive dynamics loom large. Quest Diagnostics recently delivered 7.1% year-over-year revenue growth, beating estimates by 1.9%, with shares rallying 9.4% following results. That strong showing ...

Labcorp is a global life sciences company headquartered in Burlington, North Carolina. Labcorp provides at-home test kits as well as in-person testing at their laboratory facilities, which are located ...

A large regional health system has saved more than $5 million a year on labor and supplies—and even more with capital expense avoidance—by partnering with Labcorp. Within a period of one year, Labcorp ...

Shares of Labcorp Holdings Inc. LH slipped 1.15% to $274.01 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.47% to 6,964.